Please use this identifier to cite or link to this item:
|Title:||Source document verification in the Mucopolysaccharidosis Type I Registry|
Clarke, Joe T. R.
Correa Neto, Jordao
Cox, Gerald F.
Fernhoff, Paul M.
Martins, Ana Maria [UNIFESP]
Whitley, Chester B.
Wijburg, Frits A.
Wraith, Edward J.
Koepper, Catherine M.
Genzyme Europe BV
Johannes Gutenberg Univ Mainz
Hosp Sick Children
Pontificia Univ Catolica Campinas
Childrens Hosp Boston
Hop Femme Mere Enfant
Universidade Federal de São Paulo (UNIFESP)
Childrens Mem Hlth Inst
St Marys Hosp
|Keywords:||source document verification|
enzyme replacement therapy
|Citation:||Pharmacoepidemiology and Drug Safety. San Francisco: Wiley Periodicals, Inc, v. 21, n. 7, p. 749-752, 2012.|
|Abstract:||Purpose the Mucopolysaccharidosis Type I (MPS I) Registry is an international observational database that tracks the natural history and the outcomes of patients with MPS I. the Registry was a regulatory requirement following the approval of laronidase enzyme replacement therapy for MPS I in 2003. All data are collected voluntarily after informed consent from the patient or family. Data are checked through queries, monthly reviews, and electronic audits to identify missing, inconsistent, or invalid data. This analysis sought to determine overall data accuracy in the Registry through source document verification (SDV). Methods Two phases of SDV were performed. in each phase, Registry data were compared against source documents at sites in Europe, Latin America, and North America. Three patients were randomly selected for SDV at each of the selected sites among all patients enrolled =18?months and ever receiving laronidase. Key parameters central to MPS I and its treatment were examined from the baseline and the last available assessments. Results Results indicate an overall source-to-database error rate in the MPS I Registry of 2.7% (47 discrepancies out of 1715 items; 95% confidence interval [2.2%, 3.5%]) in Phase?1 and 3.7% (64 discrepancies out of 1732 items; 95% confidence interval [2.9%, 4.7%]) in Phase?2. No systematic errors were found. Conclusions the overall error rates in both phases of SDV demonstrate acceptable data accuracy in the MPS I Registry within the data fields that were assessed. Copyright (c) 2011 John Wiley & Sons, Ltd.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.